Northern Trust’s Takeda Pharmaceutical TAK Stock Holding History

Northern Trust’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27.9M	Sell	1,740,313 -220,725	-11%	-$3.65M	﹤0.01%	1597
2026 Q1	$36.3M	Buy	1,961,038 +262,123	+15%	+$4.6M	﹤0.01%	1314
2025 Q4	$26.5M	Sell	1,698,915 -124,795	-7%	-$1.78M	﹤0.01%	1492
2025 Q3	$26.7M	Sell	1,823,710 -206,175	-10%	-$3.06M	﹤0.01%	1509
2025 Q2	$31.4M	Buy	2,029,885 +389,972	+24%	+$5.76M	﹤0.01%	1384
2025 Q1	$24.4M	Sell	1,639,913 -233,675	-12%	-$3.27M	﹤0.01%	1508
2024 Q4	$24.8M	Buy	1,873,588 +238,161	+15%	+$3.27M	﹤0.01%	1564
2024 Q3	$23.3M	Buy	1,635,427 +44,902	+3%	+$637K	﹤0.01%	1527
2024 Q2	$20.6M	Sell	1,590,525 -275,628	-15%	-$3.65M	﹤0.01%	1546
2024 Q1	$25.9M	Buy	1,866,153 +51,994	+3%	+$756K	﹤0.01%	1409
2023 Q4	$25.9M	Sell	1,814,159 -376,111	-17%	-$5.34M	﹤0.01%	1438
2023 Q3	$33.9M	Sell	2,190,270 -84,881	-4%	-$1.31M	0.01%	1189
2023 Q2	$35.7M	Sell	2,275,151 -486	-0%	-$7.96K	0.01%	1194
2023 Q1	$37.5M	Sell	2,275,637 -105,217	-4%	-$1.68M	0.01%	1137
2022 Q4	$37.1M	Buy	2,380,854 +188,267	+9%	+$2.63M	0.01%	1129
2022 Q3	$28.4M	Sell	2,192,587 -67,532	-3%	-$939K	0.01%	1229
2022 Q2	$31.7M	Buy	2,260,119 +40,761	+2%	+$582K	0.01%	1209
2022 Q1	$31.8M	Sell	2,219,358 -120,979	-5%	-$1.78M	0.01%	1355
2021 Q4	$31.9M	Buy	2,340,337 +77,503	+3%	+$1.09M	0.01%	1442
2021 Q3	$37.1M	Sell	2,262,834 -1,970,848	-47%	-$33.1M	0.01%	1320
2021 Q2	$71.3M	Sell	4,233,682 -325,344	-7%	-$5.54M	0.01%	858
2021 Q1	$83.2M	Buy	4,559,026 +179,997	+4%	+$3.24M	0.02%	758
2020 Q4	$79.7M	Buy	4,379,029 +132,842	+3%	+$2.33M	0.02%	752
2020 Q3	$75.8M	Buy	4,246,187 +429,250	+11%	+$7.82M	0.02%	679
2020 Q2	$68.4M	Buy	3,816,937 +403,825	+12%	+$7.25M	0.02%	693
2020 Q1	$51.8M	Sell	3,413,112 -332,342	-9%	-$6.02M	0.01%	757
2019 Q4	$73.9M	Sell	3,745,454 -170,219	-4%	-$3.26M	0.02%	740
2019 Q3	$67.3M	Sell	3,915,673 -147,635	-4%	-$2.55M	0.02%	752
2019 Q2	$71.9M	Sell	4,063,308 -155,542	-4%	-$2.83M	0.02%	740
2019 Q1	$85.9M	Buy	4,218,850 +803,851	+24%	+$16.2M	0.02%	622
2018 Q4	$57.4M	Buy	+3,414,999	New	+$57.7M	0.02%	764

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Northern Trust's TAK Position: Q2 2026 in Review

Northern Trust reduced its Takeda Pharmaceutical (TAK) stake by 11% in Q2 2026, selling an estimated $3.65M and leaving 1,740,313 shares worth $27.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1597.

Northern Trust first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. The position peaked at $85.9M in Q1 2019. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Northern Trust held 1,740,313 shares of Takeda Pharmaceutical worth $27.9M as of Q2 2026.
Northern Trust sold 220,725 Takeda Pharmaceutical shares in Q2 2026, an estimated $3.65M.
Takeda Pharmaceutical made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #1597 holding.
Northern Trust first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
Northern Trust's Takeda Pharmaceutical position peaked at $85.9M in Q1 2019.
378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.